Profluent, a pioneer in frontier artificial intelligence for protein design, has announced a $106 million funding round co-led by Altimeter Capital and Bezos Expeditions, with additional support from existing investors including Spark Capital, Insight Partners, and Air Street Capital. The investment brings the company’s total funding to $150 million and will fuel its mission to make biology programmable. By leveraging advanced AI models, Profluent aims to revolutionize the development of next-generation therapeutics, diagnostics, agricultural solutions, and biomanufacturing processes. The capital will support the expansion of its AI infrastructure, talent acquisition, and the scaling of its platform to accelerate the discovery and design of novel proteins with precision and speed. The company’s approach combines deep learning with biological insight to unlock new capabilities in protein engineering, positioning it at the forefront of the convergence between artificial intelligence and synthetic biology.